Clinical efficacy and correlation of clinical outcomes with in vitro susceptibility for anaerobic bacteria in patients with complicated intra-abdominal infections treated with moxifloxacin

Clinical Infectious Diseases

Volumn 53, Issue 11, 2011, Pages 1074-1080

  Goldstein, Ellie J C ^a,b   Solomkin, Joseph S ^c   Citron, Diane M ^a   Alder, Jeffrey D ^d  

^a R M ALDEN RESEARCH LABORATORY   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

^d BAYER CORPORATION   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMOXICILLIN PLUS CLAVULANIC ACID; CEFTRIAXONE; ERTAPENEM; METRONIDAZOLE; MOXIFLOXACIN; PIPERACILLIN; TAZOBACTAM;

ABDOMINAL INFECTION; ANAEROBIC BACTERIUM; ANAEROBIC INFECTION; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ANTIBIOTIC THERAPY; APPENDICITIS; ARTICLE; BACTERIUM ISOLATION; BACTEROIDES FRAGILIS; BACTEROIDES OVATUS; BACTEROIDES THETAIOTAOMICRON; BACTEROIDES UNIFORMIS; BACTEROIDES VULGATUS; CLOSTRIDIUM; CONTROLLED STUDY; DIGESTIVE SYSTEM PERFORATION; DRUG EFFICACY; ERADICATION THERAPY; GRAM NEGATIVE INFECTION; GRAM POSITIVE INFECTION; HUMAN; IN VITRO STUDY; MAJOR CLINICAL STUDY; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PEPTOSTREPTOCOCCUS; PERITONITIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME;

ANTI-BACTERIAL AGENTS; AZA COMPOUNDS; BACTERIA, ANAEROBIC; BACTEROIDES INFECTIONS; CLOSTRIDIUM INFECTIONS; HUMANS; INTRAABDOMINAL INFECTIONS; MICROBIAL SENSITIVITY TESTS; QUINOLINES; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TREATMENT OUTCOME;

EID: 80755172484     PISSN: 10584838     EISSN: 15376591     Source Type: Journal    
DOI: 10.1093/cid/cir664     Document Type: Article

References (41)

1. Mazuski JE, Solomkin JS. Intra-abdominal infections. Surg Clin North Am 2009;89:421-37, ix.
2. Solomkin JS, Mazuski JE, Bradley JS, et al. Diagnosis and management of complicated intra-abdominal infection in adults and children: guidelines by the Surgical Infection Society and the Infectious Diseases Society of America. Surg Infect (Larchmt) 2010;11:79-109.
3. Nguyen MH, Yu VL, Morris AJ, et al. Antimicrobial resistance and clinical outcome of Bacteroides bacteremia: findings of a multicenter prospective observational trial. Clin Infect Dis 2000;30:870-6. (Pubitemid 32250323)
4. Redondo MC, Arbo MD, Grindlinger J, Snydman DR. Attributable mortality of bacteremia associated with the Bacteroides fragilis group. Clin Infect Dis 1995;20:1492-6.
5. Snydman DR, Cuchural GJ Jr, McDermott L, Gill M. Correlation of various in vitro testing methods with clinical outcomes in patients with Bacteroides fragilis group infections treated with cefoxitin: a retrospective analysis. Antimicrob Agents Chemother 1992;36:540-4.
6. Goldstein EJ, Snydman DR. Intra-abdominal infections: review of the bacteriology, antimicrobial susceptibility and the role of ertapenem in their therapy. J Antimicrob Chemother 2004;53(suppl 2):ii29-36.
7. Brook I. Microbiology of polymicrobial abscesses and implications for therapy. J Antimicrob Chemother 2002;50:805-10. (Pubitemid 36032798)
8. Aldridge KE, Ashcraft D, O'Brien M, Sanders CV. Bacteremia due to Bacteroides fragilis group: distribution of species, beta-lactamase production, and antimicrobial susceptibility patterns. Antimicrob Agents Chemother 2003;47:148-53. (Pubitemid 36070356)
9. Aldridge KE, Ashcraft DS. Comparison of the in vitro activities of Bay 12-8039, a new quinolone, and other antimicrobials against clinically important anaerobes. Antimicrob Agents Chemother 1997;41: 709-11. (Pubitemid 27098431)
10. Edlund C, Sabouri S, Nord CE. Comparative in vitro activity of BAY 12-8039 and five other antimicrobial agents against anaerobic bacteria. Eur J Clin Microbiol Infect Dis 1998;17:193-5. (Pubitemid 28306268)
11. Edmiston CE, Krepel CJ, Seabrook GR, et al. In vitro activities of moxifloxacin against 900 aerobic and anaerobic surgical isolates from patients with intra-abdominal and diabetic foot infections. Antimicrob Agents Chemother 2004;48:1012-6. (Pubitemid 38280357)
12. Horn R, Robson HG. Susceptibility of the Bacteroides fragilis group to newer quinolones and other standard anti-anaerobic agents. J Antimicrob Chemother 2001;48:127-30. (Pubitemid 32684737)
13. Kleinkauf N, Ackermann G, Schaumann R, Rodloff AC. Comparative in vitro activities of gemifloxacin, other quinolones, and nonquinolone antimicrobials against obligately anaerobic bacteria. Antimicrob Agents Chemother 2001;45:1896-9. (Pubitemid 32466370)
14. MacGowan AP, Bowker KE, Holt HA, Wootton M, Reeves DS. Bay 12-8039, a new 8-methoxy-quinolone: comparative in-vitro activity with nine other antimicrobials against anaerobic bacteria. J Antimicrob Chemother 1997;40:503-9. (Pubitemid 27480483)
15. Snydman DR, Jacobus NV, McDermott LA, et al. In vitro activities of newer quinolones against Bacteroides group organisms. Antimicrob Agents Chemother 2002;46:3276-9.
16. Wexler HM, Molitoris E, Molitoris D, Finegold S. In vitro activity of moxifloxacin against 179 strains of anaerobic bacteria found in pulmonary infections. Anaerobe 2000;6:227-31. (Pubitemid 30604013)
17. Golan Y, McDermott LA, Jacobus NV, et al. Emergence of fluoroquinolone resistance among Bacteroides species. J Antimicrob Chemother 2003;52:208-13. (Pubitemid 36986881)
18. Clinical and Laboratory Standards Institute. Methods for antimicrobial susceptibility testing of anaerobic bacteria;approved standard, 7th ed. M11-A7. Wayne, PA: CLSI, 2009.
19. Snydman DR, Jacobus NV, McDermott LA, et al. Lessons learned from the anaerobe survey: historical perspective and review of the most recent data (2005-2007). Clin Infect Dis 2010;50(suppl 1): S26-33.
20. Goldstein EJ, Citron DM, Vaidya SA, et al. In vitro activity of 11 antibiotics against 74 anaerobes isolated from pediatric intraabdominal infections. Anaerobe 2006;12:63-6.
21. Goldstein EJ, Citron DM, Warren YA, Tyrrell KL, Merriam CV, Fernandez H. In vitro activity of moxifloxacin against 923 anaerobes isolated from human intra-abdominal infections. Antimicrob Agents Chemother 2006;50:148-55. (Pubitemid 43042915)
22. Behra-Miellet J, Dubreuil L, Jumas-Bilak E. Antianaerobic activity of moxifloxacin compared with that of ofloxacin, ciprofloxacin, clindamycin, metronidazole and beta-lactams. Int J Antimicrob Agents 2002;20:366-74. (Pubitemid 35300433)
23. Citron DM, Goldstein EJ, Merriam CV, Lipsky BA, Abramson MA. Bacteriology of moderate-to-severe diabetic foot infections and in vitro activity of antimicrobial agents. J Clin Microbiol 2007;45:2819-28. (Pubitemid 47417321)
24. Rink AD, Stass H, Delesen H, Kubitza D, Vestweber KH. Pharmacokinetics and tissue penetration of moxifloxacin in intervention therapy for intra-abdominal abscess. Clin Drug Investig 2008;28:71-9.
25. Stass H, Rink AD, Delesen H, Kubitza D, Vestweber KH. Pharmacokinetics and peritoneal penetration of moxifloxacin in peritonitis. J Antimicrob Chemother 2006;58:693-6. (Pubitemid 44288143)
26. Stein GE, Schooley S, Tyrrell KL, Citron DM, Nicolau DP, Goldstein EJ. Serum bactericidal activities of moxifloxacin and levofloxacin against aerobic and anaerobic intra-abdominal pathogens. Anaerobe 2008;14:8-12. (Pubitemid 351221367)
27. De Waele J, Tellado J, Alder J, et al. Efficacy and safety of moxifloxacin vs. ertapenem in complicated intra-abdominal infections: results of the PROMISE study [abstract 1549]. In: 20th ECMID. Vienna, Austria: European Society for Microbiology and Infectious Diseases, 2010.
28. Malangoni MA, Song J, Herrington J, Choudhri S, Pertel P. Randomized controlled trial of moxifloxacin compared with piperacillin-tazobactam and amoxicillin-clavulanate for the treatment of complicated intraabdominal infections. Ann Surg 2006;244:204-11. (Pubitemid 44305534)
29. Solomkin J, Zhao YP, Ma EL, Chen MJ, Hampel B. Moxifloxacin is non-inferior to combination therapy with ceftriaxone plus metronidazole in patients with community-origin complicated intra-abdominal infections. Int J Antimicrob Agents 2009;34:439-45.
30. Weiss G, Reimnitz P, Hampel B, Muehlhofer E, Lippert H. Moxifloxacin for the treatment of patients with complicated intra-abdominal infections (the AIDA Study). J Chemother 2009;21:170-80.
31. Avelox (moxifloxacin hydrochloride) tablets and Avelox IV (moxifloxacin hydrochloride in sodium chloride injection). Package insert. Bayer HealthCare Pharmaceuticals Inc, 2008.
32. Babinchak T, Ellis-Grosse E, Dartois N, Rose GM, Loh E. The efficacy and safety of tigecycline for the treatment of complicated intraabdominal infections: analysis of pooled clinical trial data. Clin Infect Dis 2005;41(suppl 5):S354-67. (Pubitemid 41170382)
33. Lucasti C, Jasovich A, Umeh O, Jiang J, Kaniga K, Friedland I. Efficacy and tolerability of IV doripenem versus meropenem in adults with complicated intra-abdominal infection: a phase III, prospective, multicenter, randomized, double-blind, noninferiority study. Clin Ther 2008;30:868-83. (Pubitemid 351799866)
34. Lee Y, Park Y, Kim MS, et al. Antimicrobial susceptibility patterns for recent clinical isolates of anaerobic bacteria in South Korea. Antimicrob Agents Chemother 2010;54:3993-7.
35. Papaparaskevas J, Pantazatou A, Katsandri A, et al. Moxifloxacin resistance is prevalent among Bacteroides and Prevotella species in Greece. J Antimicrob Chemother 2008;62:137-41. (Pubitemid 351865886)
36. Snydman DR, Jacobus NV, McDermott LA, et al. National survey on the susceptibility of Bacteroides fragilis group: report and analysis of trends in the United States from 1997 to 2004. Antimicrob Agents Chemother 2007;51:1649-55. (Pubitemid 46744140)
37. Goldstein EJC, Citron DM, Hecht DW. Resistance in anaerobic bacteria. In: Fong IW, Drlica K, eds. Antimicrobial resistance and implications for the 21st century. New York City, NY: Springer Publishing, 2008:207-29.
38. Liu CY, Huang YT, Liao CH, Yen LC, Lin HY, Hsueh PR. Increasing trends in antimicrobial resistance among clinically important anaerobes and Bacteroides fragilis isolates causing nosocomial infections: emerging resistance to carbapenems. Antimicrob Agents Chemother 2008;52:3161-8.
39. Hecht DW. Anaerobes: antibiotic resistance, clinical significance, and the role of susceptibility testing. Anaerobe 2006;12:115-21. (Pubitemid 43831678)
40. Seifert H, Dalhoff A. German multicentre survey of the antibiotic susceptibility of Bacteroides fragilis group and Prevotella species isolated from intra-abdominal infections: results from the PRISMA study. J Antimicrob Chemother 2010;65:2405-10.
41. Goldstein EJ, Citron DM, Cole RE, Rangel DM, Seid AS, Ostovari MO. Cefoxitin in the treatment of aerobic and anaerobic infections: prospective correlation of in vitro susceptibility methods with clinical outcome. Hosp Pract (Off Ed) 1990;25(suppl 4):38-45. (Pubitemid 20313279)